This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

This Week in HIV Research: How Low (an Atripla Dose) Can You Go?

1 of 5
Next >

The HIV research beat rolls ever onward, and this week's selection of featured studies from peer-reviewed journals strikes a varied and eclectic rhythm. Here's what has our brains humming this week -- that is, outside of all the blaring headlines you've likely seen about a new case of HIV remission and other important findings presented at CROI 2019:

  • Efavirenz/tenofovir/emtricitabine (Atripla) may be just as effective when taken every other day as it is when taken daily.
  • Hospitalized people with HIV -- especially marginalized people -- all too often fail to fill their antiretroviral prescriptions after discharge.
  • As the U.S. vows to end its HIV epidemic by 2030, its progress against UNAIDS targets is mixed.
  • Clustering -- and HIV coinfection -- was extremely common in hepatitis C outbreaks within a major French city.

Get those fingers tapping, and let's scroll through each of these four studies in more detail. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: franckreporter via iStock

The HIV research beat rolls ever onward, and this week's selection of featured studies from peer-reviewed journals strikes a varied and eclectic rhythm. Here's what has our brains humming this week -- that is, outside of all the blaring headlines you've likely seen about a new case of HIV remission and other important findings presented at CROI 2019:

  • Efavirenz/tenofovir/emtricitabine (Atripla) may be just as effective when taken every other day as it is when taken daily.
  • Hospitalized people with HIV -- especially marginalized people -- all too often fail to fill their antiretroviral prescriptions after discharge.
  • As the U.S. vows to end its HIV epidemic by 2030, its progress against UNAIDS targets is mixed.
  • Clustering -- and HIV coinfection -- was extremely common in hepatitis C outbreaks within a major French city.

Get those fingers tapping, and let's scroll through each of these four studies in more detail. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: franckreporter via iStock